The final sample of 524 subjects included 291 with NW and 226 with overweight/obesity
CLINICAL TRIAL EVIDENCE FOR DUAL GLP-1/GLUCAGON RAs AND TRIPLE AGONISTS IN MASH Survodutide Survodutide, a weekly dual GLP-1/GCG agonist, was assessed in a phase 2 dose-finding trial (NCT04771273) including 293 individuals with histologically confirmed MASH and fibrosis stages F1-F3 [46]
Originally designed to manage type 2 diabetes (T2D), these drugs have rapidly expanded their therapeutic reach, offering significant benefits for obesity, cardiovascular disease, and beyond
BPC-157 for IBS & Leaky Gut BPC-157 may help: Restore intestinal barrier integrity Reduce inflammation in the gut lining Normalize abnormal gut motility Support the enteric nervous system Such effects are highly relevant for Irritable Bowel Syndrome (IBS), bloating, and leaky gut conditions
Common Adverse Events: Injection site reactions and sterile abscesses Headache, flushing, or edema (especially GH analogs) Immune reactions due to peptide impurities Clinics should source only from FDA-registered 503B outsourcing facilities and use informed consent outlining: Off-label or experimental status Unknown long-term safety Potential contamination risks Patient Counseling: Avoiding Hype and Maintaining Trust Summary: Patients increasingly learn about peptides through social media, often with exaggerated or false claims
The effects of YAP and its related mechanisms in central nervous system diseases
